JPS6310712A - Composition for oral cavity application - Google Patents

Abstract

PURPOSE:To obtain the titled transparent liquid composition for oral cavity application capable of keeping its transparent appearance even after a long-term storage without causing the clouding and precipitation, by using a heat-treated dextranase as a component, thereby inactivating lipase existing in dextranase as impurity enzyme. CONSTITUTION:Stock powder of dextranase is heat-treated in the form of a solution of 5-12 pH at 40-65 deg.C for 5min-5hr and the product is compounded to obtain the objective composition. The amount of the compounded dextranase is usually 100-100,000 unit per 1g of the composition, wherein 1 unit is an amount of reducing group produced in 1min in terms of mug of glucose when determined by using dextran as the substrate. The composition can be used in the form of transparent liquid product such as mouth-washing liquid, spray- type mouth wash, etc., tooth paste, moistened dentifrice, gingiva massaging cream, etc. EFFECT:It can be compounded to tooth paste, etc., without causing the decomposition of ester-type activation agent and stably keeping the compounded components. The feeling to the oral cavity can be maintained in desirable state over a long period.

Description

DETAILED DESCRIPTION OF THE INVENTION (1) The present invention relates to an oral composition containing dextranase, and more specifically to a dextranase-containing oral composition with excellent storage stability.

The next day is about to dawn. Conventionally, as an effective method for preventing caries, dextran, a dextran-degrading enzyme, has been used to break down dental plaque, which is mainly composed of dextran, an exopolysaccharide produced by the oral bacterium Streptococcus mutans. It is known to incorporate nase into oral compositions (Japanese Patent Laid-Open No. 58-225
No. 007, No. 58-118509, No. 56-118012
No. 56-123910).

However, this type of dextranase-containing oral composition may have problems with storage stability.

For example, according to studies conducted by the present inventors, when dextranase is added to a transparent liquid oral composition such as a mouthwash, oozing or clouding occurs during long-term storage.

Therefore, as a result of conducting various studies on the cause of such cloudiness, it was found that the cause lies in lipase contained as an impurity in dextranase. That is, transparent liquid oral compositions such as mouthwashes usually contain fragrance and, in order to solubilize it, an ester nonionic surfactant having an ester bond, such as polyethylene hydrogenated castor oil, which has a high stabilizing effect against dextranase. However, when such an ester nonionic surfactant is blended,
Over time, it becomes cloudy and impairs the transparent appearance. According to the present inventors, the ester-based nonionic field generated by the esterase activity of lipase, which is an impurity enzyme of dextranase. It was thought that this was the cause of the cloudiness or cloudiness mentioned above.

Therefore, it is not desirable for a transparent liquid oral composition to become cloudy and lose its transparent appearance when stored, and therefore, even after long-term storage, it does not become cloudy and maintains its transparent appearance. A stable liquid oral composition was desired.

In addition, 1. In normal opaque appearance 'M toothpaste, etc., the formation of such a white cloud does not appear as an interlayer in appearance, but if the ester-based activator is decomposed by the esterase activity of lipase, the effect of the ester-based activator may be deteriorated. In addition, fatty acids are produced due to decomposition, resulting in a problem of poor usability.

The present invention was made in view of the above circumstances, and it is an object of the present invention to provide an oral composition that is prevented from inhibiting the stabilization of an orovaginal composition by lipase and has excellent storage stability.

Means and Effects for Solving the Problems In order to achieve the above object, the present inventors conducted further intensive research and found that by incorporating heat-treated dextranase into an oral composition, dextranase can be obtained. It has been found that the impurity enzyme lipase contained in stranase is inactivated and the oral composition is stabilized. For example, as mentioned above, the present inventors found that ester nonionic surfactants having ester bonds such as polyoxyethylene hydrogenated castor oil are decomposed by the esterase activity of lipase contained in dextranase to some extent. It has been found that decomposition products cause cloudiness or discharge in liquid oral compositions, but by including heat-treated dextranase, clear liquid oral compositions can be stored for a long period of time. It has been found that the transparent appearance is stably maintained without the occurrence of cloudiness or ooze. In addition, when such heat-treated dextranase is blended into toothpaste, etc., there is no decomposition of the ester active agent, etc., the blended amount and content are maintained stably, and the feeling of use is maintained good over a long period of time. This finding led to the present invention.

Therefore, the present invention provides an orovaginal composition characterized by containing heat-treated dextranase.5 The present invention will be described in more detail below.

The oral composition according to the present invention can be used as a transparent liquid product such as a mouthwash, a spray-type mouthwash, or a toothpaste,
It can be prepared as a moisturizing toothpaste, gum surge cream, etc., and contains heat-treated dextranase.

Here, dextranases include, but are not particularly limited to, Chaetomium sp.
Streptomyces sp.
, ), Bacillus sp.
, Corynebacterium spp.
um) etc. can be suitably used.

In addition, the amount added is usually 100 to 10 per 1 g of the composition.
0. oOO units, and preferably 500 to 50,000 units. Here, 1 unit is the amount of reducing groups produced per minute when measured using dextran as a substrate, expressed in μg in terms of glucose.

In addition, as a means for incorporating heat-treated dextranase into an oral composition, methods include heat-treating a dextranase bulk powder and blending it into an oral composition, and manufacturing a dextranase-containing oral composition. In this case, the ingredients are mixed in an appropriate order, or an appropriate mixture of ingredients is mixed with each other. At this time, the mixture for producing an oral composition containing dextranase is heat-treated, A method for obtaining an oral composition containing heat-treated dextranase by mixing with components or other mixtures, after producing an oral composition containing dextranase,
There are methods of heat-treating this, and in this way, dextranase is heat-treated alone or in a mixed state with other components, but it does not matter which step the heat treatment is carried out.

In this case, the heat treatment conditions are not necessarily limited, but from the viewpoint of deactivating dextranase, the temperature is 40 to 65 °C, especially 5 °C.
0 to 60°C, time 5 minutes to 5 hours.

In particular, it is preferable to heat-treat the dextranase for 10 minutes to 2 hours, and in order to improve the efficiency of the treatment, the pH of the dextranase-containing solution to be treated should be 5 to 12, particularly 8 to 10. It is preferable.

The oral composition according to the present invention may contain other components depending on the type thereof.

For example, water-soluble salts of alkyl sulfates having 8 to 18 carbon atoms such as sodium lauryl sulfate and sodium myristyl sulfate; water-soluble salts of alkyl sulfates having 10 to 18 carbon atoms such as sodium lauryl monoglyceride sulfate and sodium higher fatty acid monoglyceride monosulfate; higher fatty acid monoglyceride sulfate, α-olefin sulfonate, paraffin sulfonate, sodium salt of N-methyl-N-balmitoyl tauride, sodium N-lauroyl sarcosinate, sodium salt of N-lauroyl-β-alanine, etc. Anionic surfactants, sucrose fatty acid esters in which the fatty acid group has 12 to 18 carbon atoms such as sucrose mono- and dilaurate, lactose fatty acid esters, lactitol fatty acid esters, maltitol fatty acid esters, fatty acid glycerides such as stearic acid monoglyceride, Polyoxyethylene sorbitan fatty acid esters such as polyoxyethylene sorbitan monolaurate and polyoxyethylene sorbitan monostearate, polyoxyethylene, (10, 20, 40, 60° 80.100 mol)
Polyoxyethylene fatty acid esters such as hydrogenated castor oil,
Polyethylene oxide such as polyoxyethylene polyoxypropylene monolauryl ester, esters of polypropylene oxide and fatty acids, nonionic surfactants such as fatty acid alkanolamides such as lauric acid jetanolamide, cationic surfactants, and amphoteric surfactants. One or more types of surfactants such as
10% (weight %, same hereinafter) may be blended.

In this case, the present invention contains dextranase whose lipase has been deactivated by heat treatment.
Even if an ester or ester ether surfactant having an ester bond is used, it will not be decomposed by the esterase activity of lipase, so ester or ester ether surfactants can be used effectively.

Furthermore, the oral composition of the present invention includes sodium carboxymethyl cellulose and methyl cellulose.

Sodium carboxymethyl hydroxyethyl cellulose, hydroxyethyl cellulose, sodium alginate, carrageenan, gum arabic.

Binder such as xanthan gum, tragacanth gum, karaya gum, polyvinyl alcohol gum, carboxyvinyl polymer and polyvinylpyrrolidone, polyethylene glycol, ethylene glycol, sorbitol, glycerin, propylene glycol, 1,3-butylene gelicol, xylit, maltite, luffit, etc. Thickening agents, essential oils such as peppermint and spearmint, fragrance materials such as α-menthol, carvone, eugenol, anethole, etc., saccharin sodium, stevioside, neohesberidyl dihydrochalcone, glycyrrhizin, perillartine, P-methoxycinnamic aldehyde, etc. In addition to dextranase, protease, lysozyme, lytic enzyme, mutanase, sorbic acid, alexidine, β-glycyrrhetinic acid, hinokitiol, chlorhexidine, and alkylglycine are appropriately blended with flavoring agents and preservatives.

Alkyldiaminoethylglycine salt, allantoin, E
-Aminocaproic acid, tranexamic acid, sodium monofluorophosphate, sodium fluoride.

Active ingredients such as stannous fluoride, azulene, vitamin E, water-soluble primary or diphosphoric acid salts, quaternary ammonium compounds such as cetylpyridinium chloride, sodium chloride, crude drug extracts, etc. can also be blended.

In addition, an abrasive can be added to the dentifrice.

Effects of the Invention The oral composition of the present invention contains heat-treated dextranase, so that the ingredients, especially the ester components, are stably maintained and the composition has excellent storage stability.

Next, the effects of the present invention will be specifically illustrated by experimental examples.

[Experimental Example 1] Presence or absence of esterase activity and stability of dextranase when dextranase raw material is heat-treated under the treatment conditions shown in Table 1. Adding heat-treated dextranase raw material to a test solution with the following composition. death.

Appearance evaluation was performed when this was stored at room temperature for one month. The results are shown in Table 1. The method for measuring esterase activity is as follows.

Esterase activity measurement method> Substrate (20% polyoxyethylene hydrogenated castor oil solution) is reacted with dextranase under 0.1M acetate buffer (pH 5,1), and free fatty acids produced by esterase activity are measured using a conventional method. It was measured by a colorimetric method according to the method.

0: No activity.

Δ: Some activity remains.

×: Active.

Dex Dextranase 0: Residual activity is 80% or more of before treatment Δ: 50-80% ×: 50% or less Appearance of test liquid 0: Clear with no clouding or clouding.

Δ: Some white turbidity or oozing occurred.

×: There is cloudiness or formation of a cloud.

Methylparaben 0.4g Glycine 2.0g Total 200-[Experimental Example 2] Dextranase stability and appearance of test solution (room temperature, 1 week) was evaluated in the same manner as in Experimental Example 1.

Polyethylene hydrogenated castor oil 2.0% Fragrance 0.5 Glycerin 10.0 Methylparaben 0.2 Alanine 0.5 Sodium saccharin 0.02 Untreated dextranase (1 million u/g) 1.
0100, O% Hereinafter, Examples will be shown, and the appearance after storage and the results of dextranase stability evaluation will be shown, but the present invention is not limited to the following Examples.

[Examples 1 to 4] Mouth washes containing heat-treated dextranase active ingredients.

Table 3 Heat treatment conditions for bulk dextranase Table 4 [Examples 5 to 7] A mouthwash containing untreated dextranase was prepared and then heat-treated.

Table 5

Claims (1)

[Scope of Claims] 1. An oral composition characterized by containing heat-treated dextranase. 2. The composition for oral cavity according to claim 1, wherein the dextranase bulk powder is heat-treated and the heat-treated dextranase bulk powder is blended. 3. The oral composition according to claim 1, which comprises heat-treating a mixture for producing an oral composition containing dextranase and blending the heat-treated mixture. 4. The oral composition according to claim 1, which is obtained by heat-treating the oral composition containing dextranase. 5. The oral composition according to any one of claims 1 to 4, wherein the heat treatment temperature is 40 to 65°C.